Investors & Media

Sep 28, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Sep 28, 2021 / Sep 28, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

9/23/21

BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
Topline results from both studies are expected in December 2021 LAVAL, Quebec --(BUSINESS WIRE)--Sep. 23, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory...
Read More
9/13/21

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
Interim analysis met the threshold for a high probability of clinical efficacy Data from interim analysis support accelerated planning for the Phase 3 program SOOTHE Phase 2b trial is on track to deliver topline results in Q4 2021 LAVAL, Quebec --(BUSINESS WIRE)--Sep. 13, 2021-- BELLUS Health Inc....
Read More
9/2/21

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
LAVAL, Quebec --(BUSINESS WIRE)--Sep. 2, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders,...
Read More